Becton Dickinson’s $1.7 Billion Cash Engine — Free Cash Flow Jumps 45% But Is It Enough?

Becton, Dickinson and Company reported third-quarter fiscal 2026 results that reflected its transition as a focused med tech company following the spin-off of its Life Sciences segment. The company generated revenue of $5.0 billion, marking 4.4% growth on a foreign exchange-neutral basis, driven by broad-based strength in over 90% of its portfolio, with many growth platforms expanding at high single to double-digit rates. Key contributors included biologic drug delivery (notably GLP-1 therapies), advanced patient monitoring (APM), pharmacy automation via Rowa, pure Wick technology in urgent care, advanced tissue regeneration, peripheral vascular disease products, and strong performance in vascular access and specimen management in the U.S. This growth was partially offset by headwinds concentrated in less than 10% of the portfolio, primarily a challenging prior-year comparison in Alaris infusion systems and ongoing pressures in vaccines within China. These influences played out largely as anticipated by management.